Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashley Classen

Interventional Pain Medicine Fort Worth, TX Doctor of Osteopathy

NPI 1629071733 CMS profile 164877

823 Pennsylvania Ave, Fort Worth, TX 76104

Open in the dashboard

General payments

$42,933

473 records reported · program years 2019–2025

Research payments

$820

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Classen of Fort Worth, TX is reported in the CMS Open Payments database as having received $42,933 across 473 general payments and $820 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,228 36
2024 General $10,823 50
2023 General $7,023 82
2022 General $2,882 72
2021 General $7,192 59
2020 General $790 54
2020 Research $820 1
2019 General $12,995 120

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Classen
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Ashley Classen were reported at $1,228. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Ashley Classen Interventional Pain Medicine median Middle half National median
2019 $12,995 $684 $216–$2,079 $163
2020 $790 $382 $122–$1,109 $114
2021 $7,192 $552 $167–$1,554 $132
2022 $2,882 $605 $187–$1,924 $149
2023 $7,023 $671 $195–$1,915 $160
2024 $10,823 $684 $206–$1,837 $164
2025 $1,228 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic USA, Inc. $8,983 68 payments
  2. Medtronic, Inc. $8,720 98 payments
  3. Genesys Orthopedics Systems, L.L.C. $8,513 11 payments
  4. Nevro Corp. $3,674 58 payments
  5. Spinal Simplicity, LLC $2,081 30 payments
  6. Saluda Medical Americas, Inc. $2,073 9 payments
  7. Southern Spine, LLC $1,700 1 payment
  8. Vertiflex, Inc. $1,640 46 payments
  9. Boston Scientific Corporation $1,113 33 payments
  10. Nalu Medical, Inc. $795 22 payments
  11. Other $3,640 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,377 439 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,358 5 payments
  3. Consulting Fee $8,700 3 payments
  4. Travel and Lodging $5,462 24 payments
  5. Education $21 1 payment
  6. Gift $15 1 payment
Products named General payments · program years 2019–2025
  1. Sacroiliac Joint Fusion System Sacroiliac $8,513 11 payments
  2. SACROILIAC JOINT FUSION SYSTEM Sacroiliac $8,456 9 payments
  3. RESTORE $4,960 1 payment
  4. INTELLIS ADAPTIVESTIM $4,059 54 payments
  5. INTELLIS $3,728 11 payments
  6. SYNCHROMED $3,205 8 payments
  7. Evoke SCS $2,042 7 payments
  8. HA MINUTEMAN G3-R $1,971 29 payments
  9. Superion ISS $1,640 46 payments
  10. Senza Spinal Cord Stimulation System $1,458 14 payments
  11. Other $9,478 292 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic USA, Inc. $820 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

790

Median for Interventional Pain Management: 1,220

Drug cost

$30,128

Median for Interventional Pain Management: $39,344

Branded share of claims

18%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ajovy Syringe Fremanezumab-Vfrm Brand 12 $8,238
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 74 $7,097
Buprenorphine Generic 29 $3,763
Celecoxib Generic 39 $1,586
Gabapentin Generic 113 $1,557
Duloxetine Hcl Generic 106 $1,532
Methocarbamol Generic 106 $1,449
Naloxone Hcl Generic 19 $1,336
Pregabalin Generic 56 $885
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 41 $730

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$87,829

Medicare's payments for the services billed

Medicare patients

122

Average age 74

Services billed

1,005

70 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 45%
Diabetes 39%
Ischemic heart disease 38%
Chronic kidney disease 29%
Atrial fibrillation 28%
COPD 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

474 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record